5 Pulmonology Headlines You Missed in November 2025

November delivered a wave of advances across asthma, COPD, and related inflammatory airway diseases, reflecting the accelerating shift toward precision medicine in respiratory care. New data showed pulmonary rehabilitation’s unexpected anti-inflammatory impact in asthma—particularly a 40% FeNO reduction among patients who began PR with high levels—while an open-label extension of tezepelumab demonstrated substantial steroid-sparing benefits, with nearly all OCS-dependent patients tapering to 5 mg or less and half discontinuing steroids entirely. The month also brought promising phase 2b results for rezpegaldesleukin, an IL-2 receptor pathway agonist that improved both atopic dermatitis and asthma control, underscoring its potential as a dual-benefit therapy for patients with overlapping disease.